MA31014B1 - Vaccin contre la leishmania canine. - Google Patents

Vaccin contre la leishmania canine.

Info

Publication number
MA31014B1
MA31014B1 MA32020A MA32020A MA31014B1 MA 31014 B1 MA31014 B1 MA 31014B1 MA 32020 A MA32020 A MA 32020A MA 32020 A MA32020 A MA 32020A MA 31014 B1 MA31014 B1 MA 31014B1
Authority
MA
Morocco
Prior art keywords
canine
against leishmania
vaccine against
leishmania
methods
Prior art date
Application number
MA32020A
Other languages
English (en)
Inventor
Laurent Bernard Fischer
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of MA31014B1 publication Critical patent/MA31014B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES VECTEURS CONTENANT ET EXPRIMANT IN VIVO LA LEISHMANIA KMP11 OU UN ÉPITOPE DE CELLE-CI QUI PROVOQUE UNE RÉPONSE IMMUNE CONTRE LA LEISHMANIA CHEZ UN CHIEN. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS COMPRENANT LESDITS VECTEURS, DES PROCÉDÉS DE VACCINATION CONTRE LA LEISHMANIA, ET DES KITS DESTINÉS À ÊTRE UTILISÉS AVEC LESDITS PROCÉDÉS ET LESDITES COMPOSITIONS.
MA32020A 2006-11-21 2009-06-19 Vaccin contre la leishmania canine. MA31014B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86684806P 2006-11-21 2006-11-21

Publications (1)

Publication Number Publication Date
MA31014B1 true MA31014B1 (fr) 2009-12-01

Family

ID=39430543

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32020A MA31014B1 (fr) 2006-11-21 2009-06-19 Vaccin contre la leishmania canine.

Country Status (11)

Country Link
US (2) US7794736B2 (fr)
EP (1) EP2086580A2 (fr)
AR (1) AR063882A1 (fr)
BR (1) BRPI0719078A2 (fr)
CA (1) CA2670097C (fr)
IL (1) IL198897A (fr)
MA (1) MA31014B1 (fr)
MX (1) MX2009005381A (fr)
TN (1) TN2009000195A1 (fr)
TW (1) TWI478723B (fr)
WO (1) WO2008064181A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
BRPI0912768A2 (pt) * 2008-05-21 2016-05-17 Infectious Disease Res Inst vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose
GB0906906D0 (en) * 2009-04-23 2009-06-03 Univ York Nucleic acid molecule
EP3466443B1 (fr) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Vecteurs poxviraux recombinants exprimant à la fois les protéines de la rage et ox40 et vaccins fabriqués à partir de ceux-ci
WO2016073410A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615663B1 (fr) * 2003-10-24 2007-12-26 Mologen AG Produit de traitement des infections par leishmania
MX2007010073A (es) 2005-02-18 2007-10-10 Astrazeneca Ab Metodo para determinar la respuesta de los inhibidores de chk1.
EP3147296A1 (fr) * 2005-11-14 2017-03-29 Merial, Inc. Thérapie génique pour traiter l'insuffisance rénale
US8524677B2 (en) * 2006-03-13 2013-09-03 Council Of Scientific And Industrial Research DNA vaccine as immunoprophylaxis against Kala-azar

Also Published As

Publication number Publication date
TWI478723B (zh) 2015-04-01
TW200826958A (en) 2008-07-01
IL198897A (en) 2013-08-29
AR063882A1 (es) 2009-02-25
US7794736B2 (en) 2010-09-14
IL198897A0 (en) 2011-08-01
MX2009005381A (es) 2009-06-30
EP2086580A2 (fr) 2009-08-12
US20080241193A1 (en) 2008-10-02
BRPI0719078A2 (pt) 2013-12-03
US20100285066A1 (en) 2010-11-11
US8871225B2 (en) 2014-10-28
TN2009000195A1 (en) 2010-10-18
WO2008064181A2 (fr) 2008-05-29
CA2670097A1 (fr) 2008-05-29
CA2670097C (fr) 2015-10-06
WO2008064181A3 (fr) 2008-11-20

Similar Documents

Publication Publication Date Title
MA31014B1 (fr) Vaccin contre la leishmania canine.
WO2007039858A3 (fr) Imagerie et/ou therapie ciblees faisant intervenir la cycloaddition [3+2] azide-alcyne
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
EP1781593A4 (fr) Lipides cationiques et leurs procédés d'utilisation
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
PH12017502033A1 (en) Compositions and methods for controlling nematodes
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2006038185A3 (fr) Imagerie et/ou therapie ciblee comprenant l'utilisation d'une ligation de staudinger
HN2012001223A (es) Antagonistas de pcsk 9
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
PE20120630A1 (es) Inmunoconjugados dirigidos
WO2004064595A3 (fr) Produits de synthese multivalents pour applications therapeutiques et diagnostiques
NO20082837L (no) Isotopmerkede benzotiazolforbindelser som avbildningsmidler for amyloidogene proteiner
WO2008112368A3 (fr) Agents de distribution d'acide phénylalkylcarboxylique
MA29459B1 (fr) Vaccins
WO2010048394A3 (fr) Vaccin contre le virus de la peste équine
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2006138503A3 (fr) Nouveaux schémas posologiques pour contraceptifs oraux monophasiques
MA32376B1 (fr) VACCIN CONTRE LA LEISHMANIOSE UTILISANT UN IMMUNOGèNE SALIVAIRE DE PHLÉBOTOME
WO2007051169A3 (fr) Utilisation d'agents d'expansion de cellules b dans la generation d'anticorps
MA31201B1 (fr) Compositions pharmaceutiques comprenant un agent calcilytique
MX2010006509A (es) Formulaciones herbicidas para sales de trietanolamina de glifosato.